ulcerative colitis
Mebendazole (Vermox) Contraindications and Precautions
Mebendazole is rated as FDA pregnancy risk category C. Animal studies have revealed embryotoxic and teratogenic effects in pregnant rats at single oral doses as low as 10 mg/kg (approximately equal to the human dose, based on mg/m2); however, in women who inadvertently ingested mebendazole during early pregnancy, fetal effects were no different than those found in the normal population. The potential risk to the fetus must be weighed against the potential benefits of using mebendazole.
Use mebendazole cautiously in women who are breast-feeding. It is not known if mebendazole is excreted in the breast milk; some data indicates that the amounts of drug that might be excreted in human milk are clinically insignificant and below the level of normal detection. There have been no problems reported in nursing infants.
Mebendazole should be used with caution in patients with hepatic disease. Medbendazole is primarily eliminated by the liver and can accumulate in patients with hepatic impairment, increasing the risk of adverse reactions. Periodic assessment of organ system functions, including hematopoietic and hepatic, is advisable during prolonged therapy.
Mebendazole should be used with caution in patients with inflammatory bowel disease. Patients with Crohn’s disease ileitis or ulcerative colitis may have increased absorption of mebendazole with an increased risk of toxicity, especially during high dose therapy.
[ Last revised: 3/9/2004 7:12:00 PM ]
Related entries
Syndicate
